soul trial oral semaglutide cardiovascular outcomes results 2024 2025 Semaglutide's Impact on Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: Researchers to present CV findings
Description
The first dose was administered on Day 1 following surgical debulking of respiratory papillomatosis lesions with subsequent doses on Days 15, 43 and 85
The medication works by mimicking the natural GLP-1 hormone, which plays multiple roles in glucose regulation and appetite control
In type 2 diabetes, the lipid-buffering capacity of WAT is dysregulated due to nutrient surplus in excess of adipose storage capacity, reduced insulin-mediated suppression of FFAs release, lowered adipose tissue perfusion, and impaired recruitment of lipoprotein lipase (LPL) which is responsible for hydrolysis and uptake of triglycerides [45]
doi:10.1056/NEJMoa2032183 2Wilding JPH, Batterham RL, Calanna S, et al
International Journal of Molecular Science 22(18):10151
approval varies by country
